Fast Market Research announces the availability of the new Global Markets Direct report, "Prostate Cancer - Pipeline Review, H2 2015", on their comprehensive research portal

Boston, MA -- (SBWire) -- 02/15/2016 --Global Markets Direct's, 'Prostate Cancer - Pipeline Review, H2 2015', provides an overview of the Prostate Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Prostate Cancer and special features on late-stage and discontinued projects.

Get More Details on this Report and a Full Table of Contents at Prostate Cancer - Pipeline Review, H2 2015

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Report Scope

-The report provides a snapshot of the global therapeutic landscape of Prostate Cancer
-The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
-The report reviews key players involved in the therapeutics development for Prostate Cancer and enlists all their major and minor projects
-The report summarizes all the dormant and discontinued pipeline projects
-A review of the Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
-Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
-A detailed assessment of monotherapy and combination therapy pipeline projects
-Coverage of the Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type
-Latest news and deals relating related to pipeline products

Reasons to Get this Report

-Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
-Develop strategic initiatives by understanding the focus areas of leading companies
-Identify and understand important and diverse types of therapeutics under development for Prostate Cancer
-Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
-Devise corrective measures for pipeline projects by understanding Prostate Cancer pipeline depth and focus of Indication therapeutics
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
-Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned in this Report: 4SC AG, A. Menarini Industrie Farmaceutiche Riunite Srl, AB Science SA, AbbVie Inc., Acino Pharma AG, Actinium Pharmaceuticals, Inc., Adamis Pharmaceuticals Corporation, ADC Therapeutics Sarl, Aduro BioTech, Inc., Advanced Cancer Therapeutics, Advantagene, Inc., Advaxis, Inc., Aeglea BioTherapeutics, Inc., Aeterna Zentaris Inc., Aileron Therapeutics, Inc., Akshaya Bio Inc., Alchemia Limited, Alethia Biotherapeutics Inc., Almac Discovery Limited, Ambrx, Inc., Amgen Inc., Anavex Life Sciences Corp., AndroScience Corporation, AnGes MG, Inc., Angion Biomedica Corp., AntiCancer, Inc., Antigen Express, Inc., Antisense Therapeutics Limited, Aphios Corporation, APIM Therapeutics AS, Aptose Biosciences Inc., Armour Therapeutics Inc., Arno Therapeutics, Inc., ArQule, Inc., Arrien Pharmaceuticals, LLC, Arrowhead Research Corporation, Arvinas, Inc., Ascenta Therapeutics, Inc., Astellas Pharma Inc., Astex Pharmaceuticals, Inc., AstraZeneca Plc, ATLAB Pharma SAS, Avidity NanoMedicines, LLC, Avipep Pty Ltd, Axelar AB, Azaya Therapeutics, Inc., Bavarian Nordic A/S, Baxalta Incorporated, Bayer AG, Beta Pharma, Inc., Bexion Pharmaceuticals, LLC., BHR Pharma, LLC, BIND Therapeutics, Inc., Bio-Cancer Treatment International Limited, Bio-Path Holdings, Inc., Bionature E.A. Ltd., Biotest AG, Biscayne Pharmaceuticals, Inc., Blirt S.A., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Camurus AB, Can-Fite BioPharma Ltd., Cantex Pharmaceuticals, Inc., Celgene Corporation, CellCentric Ltd, Cellceutix Corporation, Celldex Therapeutics, Inc., Cellectar Biosciences, Inc., Chamaeleo Pharma NV, Champions Oncology, Inc., CohBar, Inc., Colby Pharmaceutical Company, Corcept Therapeutics Incorporated, Crescendo Biologics Limited, CureVac GmbH, CytoVac A/S, CZ BioMed Corp, DEKK-TEC, Inc., DexTech Medical AB, Dongkook Pharmaceutical Co., Ltd., DormaTarg, Inc., Eisai Co., Ltd., Eli Lilly and Company, Emergent BioSolutions Inc., Enceladus Pharmaceuticals BV, Endo Pharmaceuticals Inc., EndoCeutics, Inc., Endocyte, Inc., EntreChem, S.L., Errant Gene Therapeutics, LLC, Erytech Pharma SA, Esperance Pharmaceuticals, Inc., ESSA Pharma Inc, Eureka Therapeutics, Inc., Evgen Pharma PLC, Exonate Limited, F. Hoffmann-La Roche Ltd., Ferring International Center S.A., Forendo Pharma Limited, Foresee Pharmaceuticals, LLC, Fortress Biotech, Inc., Fountain Biopharma Inc., Fujifilm Corporation, G1 Therapeutics, Inc., Galectin Therapeutics, Inc., Galileo Research s.r.l., Genelux Corporation, Genentech, Inc., Genmab A/S, GenSpera, Inc., Gilead Sciences, Inc., Glactone Pharma AB, GlaxoSmithKline Plc, GlycoMimetics, Inc., GP Pharm, S.A., GTx, Inc., Hadasit Medical Research Services & Development Ltd, Humanetics Corporation, Huperion Sarl, Hybrigenics S.A., IC-MedTech, Inc., IGF Oncology, LLC., Ignyta, Inc., Immuneed AB, Immunocore Limited, ImmunoFrontier, Inc., Immunomedics, Inc., Immunovaccine, Inc., Incanthera Ltd., Incuron, LLC, Innate Immunotherapeutics Ltd, Inovio Pharmaceuticals, Inc., Io Therapeutics, Inc., Ipsen S.A., Johnson & Johnson, Jyant Technologies, Inc., KAEL-GemVax Co., Ltd., KaloBios Pharmaceuticals, Inc., Kancera AB, Karyopharm Therapeutics, Inc., Kite Pharma, Inc., Komipharm International Co., Ltd., Kura Oncology, Inc., Kyowa Hakko Kirin Co., Ltd., Lidds AB, Luye Pharma Group Ltd., MacroGenics, Inc., Meabco A/S, Mebiopharm Co., Ltd., MediaPharma s.r.l., MediGene AG, Mediolanum farmaceutici S.p.A., Medivation, Inc., MEI Pharma, Inc., Merck & Co., Inc., Merck KGaA, Merrion Pharmaceuticals Plc, Millennium Pharmaceuticals, Inc., Mirna Therapeutics, Inc., MolMed S.p.A., Monopar Therapeutics LLC, Morphotek, Inc., NewLink Genetics Corporation, NormOxys, Inc., Novartis AG, Novogen Limited, Nymox Pharmaceutical Corporation, Oasmia Pharmaceutical AB, Omeros Corporation, Omnitura Therapeutics Inc., OncBioMune Pharmaceuticals Inc., Oncodrone BV, Oncogenex Pharmaceuticals, Inc., Oncolix, Inc., Oncology Research International Limited, Oncolytics Biotech Inc., OncoMax, OncoNOx ApS, Oncothyreon Inc., Oncovir, Inc., OncoVista Innovative Therapies, Inc., Onyx Pharmaceuticals, Inc., ORCA Therapeutics B.V., Orion Oyj, Orphagen Pharmaceuticals, Inc., Otsuka Holdings Co., Ltd., OXiGENE, Inc., Panacela Labs, Inc., Pantarhei Bioscience BV, PDS Biotechnology Corporation, Peptron, Inc., Pfizer Inc., Pharmedartis GmbH, Pharmicell Co., Ltd., Pharminox Limited, Polaris Pharmaceuticals, Inc., Polyplus-Transfection SA, Prima BioMed Ltd., Progenics Pharmaceuticals, Inc., ProMetic Life Sciences Inc., Provenance Biopharmaceuticals Corp., PSites Pharma GmbH, Qu Biologics Inc., Quest PharmaTech Inc., RedHill Biopharma Ltd., RestorGenex Corporation, Rexahn Pharmaceuticals, Inc., Rigontec GmbH, Sanofi, Sareum Holdings Plc, SEEK Group, Serometrix, LLC, Shenogen Pharma Group Ltd., Sophiris Bio, Inc., Soricimed Biopharma Inc., Sorrento Therapeutics, Inc., Sotio a.s., Stemline Therapeutics, Inc., Sun Pharma Advanced Research Company Ltd., Sunesis Pharmaceuticals, Inc., Supratek Pharma Inc., Synta Pharmaceuticals Corp., TaiGen Biotechnology Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Takis S.r.l., Targovax AS, Tesaro, Inc., Teva Pharmaceutical Industries Limited, Theravectys SA, TheRyte Limited, Tokai Pharmaceuticals, Inc., Tolero Pharmaceuticals, Inc., TRACON Pharmaceuticals, Inc., TREAT U, S.A., TVAX Biomedical, Inc., TyrNovo Ltd., Ultimovacs AS, Vaccibody AS, ValiRx Plc, Vasgen Limited, Vaxeal Holding SA, Vaxon Biotech, Vicore Pharma AB, Vicus Therapeutics, LLC, Viralytics Ltd., ViraTherapeutics GmbH, WntResearch AB, Yungjin Pharm. Co., Ltd., Zensun (Shanghai) Sci & Tech Co., Ltd., Zymeworks Inc.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Drug Pipeline research reports at Fast Market Research

You may also be interested in these related reports:

-Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015
-Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015
-Metastatic Prostate Cancer - Pipeline Review, H2 2015
-Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2015
-Pancreatic Cancer - Pipeline Review, H2 2015